Biomea Fusion (BMEA) Fireside chat summary

Introduction and agenda

• The session was part of the 2026 JPMorgan Biotech Conference call series, focusing on Biomea Fusion and their pipeline updates, with a Q&A format to cover key clinical programs and upcoming data releases.

Background and experience of the speaker

• Thorsten Kirschberg, responsible for BMF-650's development, provided detailed insights into the molecule's design and clinical strategy.

Current industry trends

• Oral GLP-1 receptor agonists are a major focus, with attention on improving pharmacokinetics and tolerability compared to existing agents.

• The competitive landscape is evolving, with benchmarks set by orforglipron and recent significant deals for oral agents.